Navigation Links
Champions Oncology Reports Fiscal 2012 Second Quarter Financial Results
Date:12/14/2011

t facilitate comparisons between periods before and after certain items that would not otherwise be apparent on a GAAP basis.  Certain unusual or non-recurring items that management does not believe affect the Company's basic operations do not meet the GAAP definition of unusual or non-recurring items.  Non-GAAP net loss and non-GAAP loss per share are not, and should not be viewed as a substitute for similar GAAP items.  We define non-GAAP diluted loss per share amounts as non-GAAP net loss divided by the weighted average number of diluted shares outstanding.  Our definition of non-GAAP net loss and non-GAAP diluted loss per share may differ from similarly named measures used by others.

Full details of the Company's financial results will be available in the Company's Form 10-Q at www.championsoncology.com.

About Champions Oncology, Inc.
Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs.  The Company's Tumorgraft™ Technology Platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or Tumorgrafts™, in a manner that preserves the biological characteristics of the original human tumor.  The Company uses this technology in conjunction with related services to offer solutions for two customer groups:  Personalized Oncology Solutions ("POS") in which physicians and patients looking for information help guide the development of personalized treatment plans, and Translational Oncology Solutions ("TOS") in which pharmaceutical and biotech companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs and increasing the adoption of existing drugs. The Compan
'/>"/>

SOURCE Champions Oncology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
2. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
3. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
4. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
5. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
6. Higher Education Leaders Receive TCWF Champions of Health Professions Diversity Award
7. Champions Biotechnology Announces Agreement With Cephalon for the Evaluation of a Novel Oncology Compound Using Predictive Biomerk Tumorgraft™ Platform
8. Champions Biotechnology Awarded $1.46 million in Grants
9. Champions CFO Resigns
10. Champions Biotechnology Exercises Option to License Proprietary Compound Based on Successful Tumorgraft™ Test Results
11. Five Californians Selected as Breakaway from Cancer® Champions to be Honored During Amgen Tour of California
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... SPAIN, Trinidad and Tobago , July 25, ... of the Trinidad & Tobago Ministry of Health ... innovative therapy that significantly increases the cure rate ... patients infected with the genotype 1 virus. Telaprevir ... under the trade brand INCIVO®. Photo ...
(Date:7/25/2014)... , July 25, 2014 According ... Research "Global and China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, ... Size, Share, Growth, Trends and Forecast (Value and Volume), ... at USD 19.99 billion in 2012 and is expected ... to 2019 to reach USD 32.24 billion in 2019. ...
(Date:7/25/2014)... 25, 2014  AMETEK, Inc. (NYSE: AME ... Goos as Vice President and General Manager, Engineered ... (EMIP) Division. "I am pleased that Kurt ... business development experience, especially in the medical device industry, ... the continued growth and success of our medical components ...
Breaking Medicine Technology:The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2
... Pharmaceuticals, Inc. (NASDAQ: OPTR ) announced today ... antibiotics in two Phase 3 clinical trials exploring the ... adult patients with Clostridium difficile -associated diarrhea (CDAD) ... Clinical Infectious Diseases (CID). The analysis found ...
... 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, ... CMED ), a leading China-based advanced ... unaudited financial results for the first ... ("1Q FY2011") today.1 Q FY20 ...
Cached Medicine Technology:Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimer's DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin 2Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimer's DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin 3Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimer's DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin 4Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimer's DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin 5Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimer's DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin 6China Medical Technologies Reports First Fiscal Quarter Financial Results 2China Medical Technologies Reports First Fiscal Quarter Financial Results 3China Medical Technologies Reports First Fiscal Quarter Financial Results 4China Medical Technologies Reports First Fiscal Quarter Financial Results 5China Medical Technologies Reports First Fiscal Quarter Financial Results 6China Medical Technologies Reports First Fiscal Quarter Financial Results 7China Medical Technologies Reports First Fiscal Quarter Financial Results 8China Medical Technologies Reports First Fiscal Quarter Financial Results 9China Medical Technologies Reports First Fiscal Quarter Financial Results 10China Medical Technologies Reports First Fiscal Quarter Financial Results 11China Medical Technologies Reports First Fiscal Quarter Financial Results 12China Medical Technologies Reports First Fiscal Quarter Financial Results 13China Medical Technologies Reports First Fiscal Quarter Financial Results 14China Medical Technologies Reports First Fiscal Quarter Financial Results 15China Medical Technologies Reports First Fiscal Quarter Financial Results 16China Medical Technologies Reports First Fiscal Quarter Financial Results 17China Medical Technologies Reports First Fiscal Quarter Financial Results 18China Medical Technologies Reports First Fiscal Quarter Financial Results 19
(Date:7/26/2014)... According to the "Get Rid Tattoo ... a comprehensive guide that provides readers with safe and ... book also teaches them how to fade dark colored ... their own home for drastic results. , Vkool ... book includes step-by-step tutorials and product recommendations for treating ...
(Date:7/25/2014)... 26, 2014 PersonalInjurySolicitorsIreland, a legal ... to people who have suffered from a variety ... both their new company, and a website, ... new website explained, http://www.personalinjurysolicitorsireland.com/personal-injury-claims , the law ... of the company is always on the client, ...
(Date:7/25/2014)... (PRWEB) July 26, 2014 According ... Monitoring Market by Product (vibration monitoring, thermography, ultrasound ... signature analysis), Component, Application and Geography - Global ... the machine health monitoring market is expected to ... 2014 to 2020. , Browse 117 market data ...
(Date:7/25/2014)... 2014 As reported by the New Orleans ... Increasing (7/3), the state of Louisiana has recently seen ... even than cocaine. Officials believe the increase is due to ... “form” of marijuana. However, both doctors and police confirm that ... as to call it “poison,” doctors have acknowledged that the ...
(Date:7/25/2014)... Gerontological Society of America (GSA) the ... of aging has chosen Heather M. Young, ... Davis, as the 2014 recipient of the Doris ... honor, presented by GSA,s Health Sciences Section, is ... recognition of outstanding and sustained contribution to gerontological ...
Breaking Medicine News(10 mins):Health News:"Get Rid Tattoo Naturally" Book Review Exposes Jason Carter's Tattoo Removal Guide – Vkool.com 2Health News:"Get Rid Tattoo Naturally" Book Review Exposes Jason Carter's Tattoo Removal Guide – Vkool.com 3Health News:PersonalInjurySolicitorsIreland.com Announces the Launch of their New Company and Website 2Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 4Health News:Louisiana Recognizes Dangers of Synthetic Marijuana 2Health News:Young earns GSA's 2014 Doris Schwartz Gerontological Nursing Research Award 2
... BRUNSWICK, N.J., May 29 Johnson & Johnson,will ... & Diagnostics,businesses, as well as an update on ... 8:30 a.m. (Eastern Time) on Thursday,June 5, 2008, ... N.J., Donald Casey, Worldwide Chairman, Comprehensive Care ...
... program follows highly successful free antibiotic program ... date, GRAND RAPIDS, Mich., May 29 Supercenter ... in all 181 Meijer,pharmacies beginning June 1. The announcement ... for the Grand Rapids, Mich.-based retail chain., "As ...
... Three of the most terrifying words in,the English language ... and the fear factor rises even higher, since prostate cancer ... with early,detection is very curable., Give a gift of ... simple,blood test to screen for prostate cancer. If there is ...
... Physiology and Exercise Metabolism (Montana WPEM) will present a ... American College of Sports Medicine, showing that wildland ... supplement, Wellmune WGP, had far fewer 23 ... similar group of firefighters taking a placebo. , Montana ...
... Caraco Pharmaceutical,Laboratories, Ltd. (Amex: CPD ) posted record ... March 31, 2008 (Fiscal 2008), of $191.8 million,and $350.4 ... for the corresponding periods of Fiscal 2007. Net income ... quarter and Fiscal 2008,respectively, as compared to net income ...
... ... through in silence, COSTA MESA, Calif., May 29 ... see healthy hair, they now see,an increasing proportion of scalp. Agonizing over ... sometimes even hair,extensions, which can actually further damage already stressed-out hair., ...
Cached Medicine News:Health News:Meijer Pharmacies to Offer Free Pre-Natal Vitamins 2Health News:Give the Man in Your Life the Gift of Health 2Health News:Montana Center for Work Physiology and Exercise Metabolism presents firefighter health study 2Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008 2Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008 3Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008 4Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008 5Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008 6Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008 7Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008 8Health News:Hair Loss Is on the Rise, and Women Are Among the Hardest Hit 2
For the direct quantitative determination of low density lipoprotein cholesterol (LDL-C) in human serum or plasma. For in vitro diagnostic use only....
Storage temperature: 2 - 8C, linearity: 0 - 25 mg/dL, expected value: male: 3.5 - 7.0 mg/dL and female: 2.5 - 6.0 mg/dL. Available with calibrator and number of test 500....
Storage temperature: 15 - 30C, linearity: 0 - 20 mg/dL, expected value: male: 3.0 - 7.0 mg/dL and female: 2.2 - 6.2 mg/dL. Available with calibrator and number of tests 125....
The assay kit is for determination of uric acid in serum or urine. Wavelength: 600 nm. Linear range: up to 80 mg/dL....
Medicine Products: